Results from a new Cleveland Clinic-led study suggest that melatonin, a hormone that regulates the sleep-wake cycle and is commonly used as an over-the-counter sleep aid, may be a viable treatment option for COVID-19.<\/p>\n
As COVID-19 continues to spread throughout the world, particularly with cases rising during what some have termed the \u201cfall surge,\u201d repurposing drugs already approved by the U.S. Food and Drug Administration for new therapeutic purposes continues to be the most efficient and cost-effective approach to treat or prevent the disease.<\/p>\n
According to the findings<\/a> published today in PLOS Biology<\/em>, a novel artificial intelligence platform developed by Lerner Research Institute researchers to identify possible drugs for COVID-19 repurposing has revealed melatonin as a promising candidate.<\/p>\n Analysis of patient data from Cleveland Clinic\u2019s COVID-19 registry also revealed that melatonin usage was associated with a nearly 30 percent reduced likelihood of testing positive for SARS-CoV-2 (the virus that causes COVID-19) after adjusting for age, race, smoking history and various disease comorbidities. Notably, the reduced likelihood of testing positive for the virus increased from 30 to 52 percent for African Americans when adjusted for the same variables.<\/p>\n Read it all<\/a>.<\/p>\n Lerner Research Institute News – Cleveland Clinic Researchers Use \u201cBig Data\u201d Approach to Identify Melatonin as Possible COVID-19 Treatment https:\/\/t.co\/dljLfmHJEg<\/a> via @CCLRI<\/a><\/p>\n — Feixiong Cheng (@FeixiongCheng) November 10, 2020<\/a><\/p><\/blockquote>\n \n